US 11,938,118 B2
Analgesic and antipruritic pharmaceutical composition and application thereof
Changgeng Peng, Shanghai (CN); Liting Sun, Shanghai (CN); and Ruilong Xia, Shanghai (CN)
Assigned to SHANGHAI RUIHUKANG PHARMACEUTICAL PARTNERSHIP (LIMITED PARTNERSHIP), Shanghai (CN)
Filed by SHANGHAI RUIHUKANG PHARMACEUTICAL PARTNERSHIP (LIMITED PARTNERSHIP), Shanghai (CN)
Filed on Feb. 20, 2023, as Appl. No. 18/171,431.
Application 18/171,431 is a continuation of application No. PCT/CN2021/072071, filed on Jan. 15, 2021.
Claims priority of application No. 202010845095.2 (CN), filed on Aug. 20, 2020.
Prior Publication US 2023/0201170 A1, Jun. 29, 2023
Int. Cl. A01N 43/00 (2006.01); A01N 43/46 (2006.01); A61K 31/4164 (2006.01); A61K 31/427 (2006.01); A61K 31/55 (2006.01); A61K 47/02 (2006.01); A61K 47/36 (2006.01); A61P 25/04 (2006.01)
CPC A61K 31/427 (2013.01) [A61K 31/4164 (2013.01); A61K 47/02 (2013.01); A61K 47/36 (2013.01); A61P 25/04 (2018.01)] 9 Claims
 
1. An analgesic and antipruritic pharmaceutical composition, comprising:
PF-05089771 shown as

OG Complex Work Unit Chemistry
 and
PF-04885614 shown as

OG Complex Work Unit Chemistry
wherein the analgesic and antipruritic pharmaceutical composition is for treatment of diseases in which both a voltage-gated sodium channel 1.7 (Nav1.7) and a voltage-gated sodium channel 1.8 (Nav1.8) are involved.